Milestone Pharmaceuticals financials
$0.8200+3.09%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 |
|---|---|---|---|---|---|---|---|
| Revenue | $1.5M | $0.00 | $1.0M | $5.0M | $15.0M | — | — |
| Gross profit | $1.5M | $0.00 | $1.0M | $5.0M | $15.0M | — | — |
| Gross margin | 100.0% | — | 100.0% | 100.0% | 100.0% | — | — |
| Operating income | -$62.1M | -$42.1M | -$61.1M | -$59.6M | -$43.1M | -$50.7M | -$57.9M |
| Net income | -$63.1M | -$41.5M | -$59.7M | -$58.4M | -$42.9M | -$50.0M | -$55.2M |
| Net margin | −4078.8% | — | −5968.5% | −1167.8% | −285.7% | — | — |
| Diluted EPS | $-0.75 | $-0.67 | $-1.39 | $-1.38 | $-1.02 | $-1.70 | $-3.50 |
| EBITDA | -$62.0M | -$42.0M | -$61.0M | -$59.6M | -$43.0M | -$50.6M | -$57.8M |
| Operating cash flow | -$49.0M | -$28.8M | -$46.4M | -$52.5M | -$33.2M | -$50.7M | -$51.2M |
| Free cash flow | -$49.3M | -$28.9M | -$46.5M | -$52.7M | — | — | -$51.6M |
| Diluted shares | 83.9M | 62.2M | 43.0M | 42.5M | 41.8M | 29.3M | 15.8M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $73.0M | $25.3M | $13.8M | $7.6M | $114.1M | $72.3M |
| Short-term investments | $32.9M | $44.4M | $52.2M | $56.9M | — | $70.0M |
| Total debt | $57.2M | $53.4M | $49.8M | $0.00 | $0.00 | $0.00 |
| Total assets | $113.6M | $75.5M | $75.2M | $74.5M | $119.8M | $150.0M |
| Total liabilities | $127.4M | $115.4M | $58.5M | $8.1M | $7.2M | $6.9M |
| Shareholders' equity | -$13.9M | -$39.9M | $16.8M | $66.3M | $112.6M | $143.1M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology